Myasthenia Gravis - A Pipeline Analysis Report

Overview of the drug development for myasthenia gravis

Myasthenia gravis is one of the most common neurological disorders causing weakness in the skeleton muscles. It is likely to happen more when the connection between the muscles and the nerve cells become impaired. Both genetic and immunological abnormalities at the neuromuscular junctions (NMJ) are the common cause for myasthenia gravis. At present, there is no cure for the disease, but it can be treated well with long-term medications. One of the key symptoms of myasthenia gravis is weakness, mainly in the muscles that are under the voluntary control of an individual. It can worsen if not treated on time. For people with myasthenia gravis, it is difficult to swallow, and the neck and limb muscles become weak. Myasthenia gravis is a disorder of neuromuscular transmission, resulting from the binding of autoantibodies to the components of NMJs, most commonly the acetocholine receptor (AChR). Technavio’s market research analysts suggest that rising incidences of myasthenia gravis is expected to boost the drug development for myasthenia gravis.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of myasthenia gravis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development for the treatment of myasthenia gravis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• GlaxoSmithKline
• Novartis
• Pfizer

Therapeutic assessment of the drug development for myasthenia gravis by route of administration

• Intravenous
• Subcutaneous
• Oral
• Oral/intravenous

The intravenous route of administration (ROA) involves the application of the drug directly administered through veins, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for myasthenia gravis by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for myasthenia gravis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for myasthenia gravis?
• What are the companies that are currently involved in the drug development for myasthenia gravis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.